A non-randomized, open-label, dose escalation study of a single intracerebroventricular (ICV) administration of a gene replacement therapy in subjects who are 2 to 18 years old with NGLY1 Deficiency.

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

A Phase 1/2/3 Open-label, Single Arm, Dose-finding Study to Investigate Long-term Safety, Tolerability and Efficacy of GS-100, an Adeno-associated Virus Serotype 9 (AAV9) Vector-mediated Gene Transfer of Human NGLY1, in Patients With NGLY1 Deficiency

Treatment Trials

Filter & Search

Clinical Trial Results

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency